CA2795109C - New polymorph - Google Patents
New polymorph Download PDFInfo
- Publication number
- CA2795109C CA2795109C CA2795109A CA2795109A CA2795109C CA 2795109 C CA2795109 C CA 2795109C CA 2795109 A CA2795109 A CA 2795109A CA 2795109 A CA2795109 A CA 2795109A CA 2795109 C CA2795109 C CA 2795109C
- Authority
- CA
- Canada
- Prior art keywords
- solid form
- tetrahydro
- dimethylamide
- proline
- benzazepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- RUOLFWZIFNQQGH-DEOSSOPVSA-N (2s)-2-n,2-n-dimethyl-1-n-[[2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]methyl]pyrrolidine-1,2-dicarboxamide Chemical compound CN(C)C(=O)[C@@H]1CCCN1C(=O)NCC1=CC=C(C(=O)N2C3=CC=CC=C3CCCC2)C=C1C RUOLFWZIFNQQGH-DEOSSOPVSA-N 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims description 39
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 23
- 238000002329 infrared spectrum Methods 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 9
- 102000000370 Vasopressin V2 receptors Human genes 0.000 claims description 8
- 108050008930 Vasopressin V2 receptors Proteins 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 5
- 150000004682 monohydrates Chemical class 0.000 claims description 4
- 206010029446 nocturia Diseases 0.000 claims description 4
- 208000004880 Polyuria Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000008967 Enuresis Diseases 0.000 claims description 2
- 208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 208000028235 central diabetes insipidus Diseases 0.000 claims description 2
- 201000010064 diabetes insipidus Diseases 0.000 claims description 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 2
- 201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 claims description 2
- 208000005346 nocturnal enuresis Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 239000000203 mixture Substances 0.000 description 28
- 238000000034 method Methods 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 22
- 239000013078 crystal Substances 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- 239000000725 suspension Substances 0.000 description 14
- 238000000113 differential scanning calorimetry Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 102000004136 Vasopressin Receptors Human genes 0.000 description 11
- 108090000643 Vasopressin Receptors Proteins 0.000 description 11
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 10
- 108010004977 Vasopressins Proteins 0.000 description 10
- 102000002852 Vasopressins Human genes 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000002336 sorption--desorption measurement Methods 0.000 description 10
- 229960003726 vasopressin Drugs 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 238000013480 data collection Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000001878 scanning electron micrograph Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000003109 Karl Fischer titration Methods 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 230000002686 anti-diuretic effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229960004281 desmopressin Drugs 0.000 description 3
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical group C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- -1 1-(2-methy1-4-(2 Chemical class 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 229910002483 Cu Ka Inorganic materials 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229940083335 Vasopressin agonist Drugs 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MLLMAIJXIZOSFS-LURJTMIESA-N (2s)-n,n-dimethylpyrrolidine-2-carboxamide Chemical compound CN(C)C(=O)[C@@H]1CCCN1 MLLMAIJXIZOSFS-LURJTMIESA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 238000001530 Raman microscopy Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 210000001883 posterior pituitary gland Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1005623.2A GB201005623D0 (en) | 2010-04-01 | 2010-04-01 | New polymorph |
| GB1005623.2 | 2010-04-01 | ||
| US34704810P | 2010-05-21 | 2010-05-21 | |
| US61/347,048 | 2010-05-21 | ||
| PCT/GB2011/000500 WO2011121308A1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2795109A1 CA2795109A1 (en) | 2011-10-06 |
| CA2795109C true CA2795109C (en) | 2018-04-17 |
Family
ID=42228830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2795109A Expired - Fee Related CA2795109C (en) | 2010-04-01 | 2011-03-31 | New polymorph |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9079881B2 (enExample) |
| EP (1) | EP2552910B1 (enExample) |
| JP (1) | JP5802737B2 (enExample) |
| KR (1) | KR101792621B1 (enExample) |
| CN (1) | CN102918038B (enExample) |
| CA (1) | CA2795109C (enExample) |
| DK (1) | DK2552910T3 (enExample) |
| ES (1) | ES2538085T3 (enExample) |
| GB (1) | GB201005623D0 (enExample) |
| HR (1) | HRP20150513T1 (enExample) |
| HU (1) | HUE026442T2 (enExample) |
| ME (1) | ME02102B (enExample) |
| MX (1) | MX2012011382A (enExample) |
| PL (1) | PL2552910T3 (enExample) |
| PT (1) | PT2552910E (enExample) |
| RS (1) | RS53956B1 (enExample) |
| RU (1) | RU2559633C2 (enExample) |
| SI (1) | SI2552910T1 (enExample) |
| SM (1) | SMT201500107B (enExample) |
| WO (1) | WO2011121308A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201105537D0 (en) * | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
| CN103755707B (zh) * | 2013-09-17 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅱ及其制备方法和用途 |
| CN104059070B (zh) * | 2013-09-17 | 2016-02-10 | 天津药物研究院有限公司 | 利希普坦晶型ⅰ及其制备方法和用途 |
| CN103694240B (zh) * | 2013-09-18 | 2015-11-18 | 天津药物研究院 | 利希普坦的溶剂合物及其制备方法和用途 |
| CN104140429B (zh) * | 2014-07-25 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅴ及其制备方法和用途 |
| EP4616852A3 (en) | 2015-07-22 | 2025-10-22 | Anavex Life Sciences Corp. | Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions |
| WO2020154581A1 (en) | 2019-01-24 | 2020-07-30 | Assia Chemical Industries Ltd | Solid state forms of fedovapagon-salicyclic acid co-crystal |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW359669B (en) | 1995-12-15 | 1999-06-01 | Otsuka Pharma Co Ltd | Benzazepine derivatives |
| ES2229523T3 (es) | 1997-07-30 | 2005-04-16 | Wyeth | Agonistas triciclicos de la vasopresina. |
| IL133788A0 (en) | 1997-07-30 | 2001-04-30 | American Home Prod | Tricyclic vasopressin agonists |
| WO2000046227A1 (en) | 1999-02-04 | 2000-08-10 | American Home Products Corporation | Thienylbenzoylbenzazepines as vasopressin agonists |
| PT1149096E (pt) | 1999-02-04 | 2003-03-31 | Wyeth Corp | N-oxidos de piridina triciclicos agonistas de vasopressina |
| WO2000046228A2 (en) | 1999-02-04 | 2000-08-10 | American Home Products Corporation | Pyrrolobenzodiazepine carboxyamide vasopressin agonists |
| CN1339035A (zh) | 1999-02-04 | 2002-03-06 | 美国家用产品公司 | 吡啶并苯并二吖庚因和吡啶并苯并氧杂吖庚因酰胺血管加压素激动剂 |
| GB0000079D0 (en) * | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
-
2010
- 2010-04-01 GB GBGB1005623.2A patent/GB201005623D0/en not_active Ceased
-
2011
- 2011-03-31 CN CN201180026714.4A patent/CN102918038B/zh not_active Expired - Fee Related
- 2011-03-31 EP EP11714079.8A patent/EP2552910B1/en active Active
- 2011-03-31 SI SI201130487T patent/SI2552910T1/sl unknown
- 2011-03-31 DK DK11714079T patent/DK2552910T3/en active
- 2011-03-31 RS RS20150258A patent/RS53956B1/sr unknown
- 2011-03-31 US US13/637,873 patent/US9079881B2/en not_active Expired - Fee Related
- 2011-03-31 JP JP2013501934A patent/JP5802737B2/ja not_active Expired - Fee Related
- 2011-03-31 KR KR1020127028111A patent/KR101792621B1/ko not_active Expired - Fee Related
- 2011-03-31 HU HUE11714079A patent/HUE026442T2/en unknown
- 2011-03-31 ME MEP-2015-56A patent/ME02102B/me unknown
- 2011-03-31 ES ES11714079.8T patent/ES2538085T3/es active Active
- 2011-03-31 WO PCT/GB2011/000500 patent/WO2011121308A1/en not_active Ceased
- 2011-03-31 MX MX2012011382A patent/MX2012011382A/es active IP Right Grant
- 2011-03-31 RU RU2012146544/04A patent/RU2559633C2/ru not_active IP Right Cessation
- 2011-03-31 PT PT117140798T patent/PT2552910E/pt unknown
- 2011-03-31 HR HRP20150513TT patent/HRP20150513T1/hr unknown
- 2011-03-31 CA CA2795109A patent/CA2795109C/en not_active Expired - Fee Related
- 2011-03-31 PL PL11714079T patent/PL2552910T3/pl unknown
-
2015
- 2015-05-05 SM SM201500107T patent/SMT201500107B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101792621B1 (ko) | 2017-11-02 |
| HUE026442T2 (en) | 2016-06-28 |
| RU2012146544A (ru) | 2014-05-10 |
| RU2559633C2 (ru) | 2015-08-10 |
| KR20130023218A (ko) | 2013-03-07 |
| CA2795109A1 (en) | 2011-10-06 |
| GB201005623D0 (en) | 2010-05-19 |
| JP2013523706A (ja) | 2013-06-17 |
| DK2552910T3 (en) | 2015-04-07 |
| ME02102B (me) | 2015-10-20 |
| CN102918038A (zh) | 2013-02-06 |
| PL2552910T3 (pl) | 2015-07-31 |
| HRP20150513T1 (hr) | 2015-06-05 |
| SI2552910T1 (sl) | 2015-06-30 |
| SMT201500107B (it) | 2015-07-09 |
| MX2012011382A (es) | 2013-01-29 |
| US20140296213A1 (en) | 2014-10-02 |
| EP2552910A1 (en) | 2013-02-06 |
| EP2552910B1 (en) | 2015-03-11 |
| RS53956B1 (sr) | 2015-08-31 |
| US9079881B2 (en) | 2015-07-14 |
| WO2011121308A1 (en) | 2011-10-06 |
| ES2538085T3 (es) | 2015-06-17 |
| CN102918038B (zh) | 2015-09-09 |
| PT2552910E (pt) | 2015-05-13 |
| JP5802737B2 (ja) | 2015-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2552910B1 (en) | New polymorph | |
| AU2012331395B2 (en) | Ivabradine hydrochloride form IV | |
| KR20240167881A (ko) | 5-meo-dmt의 결정질 브롬화수소염 | |
| WO2019062854A1 (zh) | 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途 | |
| CN109336881B (zh) | 一种利伐沙班晶体 | |
| Liang et al. | Synthesis and structural characterization of two novel olanzapine cocrystals with decreased or enhanced dissolution rate | |
| WO2021213493A1 (zh) | 二氢萘啶类化合物的晶型及其用途 | |
| EP4317133B1 (en) | Crystalline form of pyrrole amide compound, preparation method therefor and use thereof | |
| CA2867781C (en) | Process for the preparation of 1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl) benzylcarbamoyl)-l-proline-n,n-dimethylamide | |
| EP2547681B1 (en) | Tosylate salt of cyclopropanecarboxylic acid 4-(6-chloro-3-metyhl-4,10-dihydro-3h-2,3,4,9-tetrabenzo[f]azulene-9-carbonyl)-2-fluorobenzylamide | |
| US20200283381A1 (en) | Solid state forms of elafibranor | |
| US9981912B2 (en) | Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof | |
| ZA200508640B (en) | Crystal of benzimidazole derivative and process for producing the same | |
| WO2023123742A1 (zh) | PI3Kδ/γ双重抑制剂化合物的半富马酸盐结晶及其制备方法 | |
| HK1193612B (en) | Process for the preparation of 1 - ( 2 -methyl - 4 - ( 2, 3, 4, 5 - tetrahydro - 1 - benzazepin- 1 -ylcarbonyl) benzylcarbamoyl) - l - proline - n, n- dimethylamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160321 |
|
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |